BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25318926)

  • 1. Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.
    Jacob J; Belin L; Pierga JY; Gobillion A; Vincent-Salomon A; Dendale R; Beuzeboc P; Campana F; Fourquet A; Kirova YM
    Breast Cancer Res Treat; 2014 Nov; 148(2):345-53. PubMed ID: 25318926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
    Karasawa K; Saito M; Hirowatari H; Izawa H; Furuya T; Ozawa S; Ito K; Suzuki T; Mitsuhashi N
    Breast Cancer; 2013 Jul; 20(3):254-61. PubMed ID: 22274798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
    Skowronek J; Piotrowski T
    Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
    PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
    Jacob J; Belin L; Gobillion A; Daveau-Bergerault C; Dendale R; Beuzeboc P; Campana F; Bollet MA; Fourquet A; Kirova YM
    Cancer Radiother; 2013 Jun; 17(3):183-90. PubMed ID: 23499212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
    Cutuli B; Dalenc F; Cottu PH; Gligorov J; Guastalla JP; Petit T; Amrate A
    Cancer Radiother; 2015 Aug; 19(5):295-302. PubMed ID: 26188735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Regional Nodal Irradiation on the Outcomes of N1 Breast Cancer Patients Referred for Adjuvant Treatment: A Patient-Level Pooled Analysis of 2 Clinical Trials.
    Abdel-Rahman O
    Clin Breast Cancer; 2018 Dec; 18(6):504-510. PubMed ID: 30115454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
    Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
    Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
    Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer in very young women.
    Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
    Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.